



REVOLUTIONIZE YOUR DRUG DISCOVERY

WWW.HELIGENICS.COM

About Us

- **Heligenics' proven breakthroughs in biotechnology power our GigaAssay™ to deliver high-quality biologic leads – at accelerated 4x speed!**
- **Our GigaAssay generates a MEGA-MAP™ activity and variant landscape**
- **Outpace the competition – Heligenics supercharges biologics discovery that is scalable at a significantly lower cost**

Tackling Hepatitis D: A Massive Opportunity

- Up to 25 million people globally are infected with hepatitis D (HDV) – the deadliest form of viral hepatitis – accelerating liver damage in millions already battling hepatitis B
- Current clinical approaches and their limitations
 - IFN- α , a treatment molecule, **boosts immune response against HDV** but is **cytotoxic, unstable, and immunogenic** – limiting its effectiveness over time
 - Bulevirtide is breaking ground as a targeted HDV therapy – but **extended efficacy is uncertain**, and it's **not yet FDA-approved**
- Challenges in new IFN- α drug development
 - **High costs and long timelines** limit pre-clinical development
 - **Slow, tedious methods** are choking innovation and stalling lead discovery

IFN- α Solution

Biobetter for Leukemia

GigaAssay: proprietary technology that drives market-shifting cost savings.

- 4X faster
- 90%+ success in validation of lead¹ generation

Market Opportunity	Heligenics Solutions
Increase potency	Rapidly pinpoint potent IFN- α variants from 100k+ leads to reduce dosing and side effects
Improved stability	Discover stable leads that reduce dosing – no guesswork
Reduced immunogenicity	Engineered for immune stealth – maximize efficacy over time
Oral forms	Unlock oral delivery with innovative molecular tweaks and natural modifications
Customized biologics	MEGA-Map landscapes reveal full variant activity 4x faster than conventional single-track technology

¹prioritized drug candidates

Our GigaAssay Technology for Discovery of Next-Generation IFN- α Drug Leads

Our patented GigaAssay leverages Heligenics' technology to rapidly screen >100k IFN- α variants for precise, highly impactful results

- **Breakthrough efficiency: lower costs, faster launch**
- **Discovery and lead verification 4x faster than conventional methods**
 - Less than one year with GigaAssay vs US average of 4.5 years
 - Rapid asset validation: *A single GigaAssay will deliver up to 50 actionable leads in <1 year*
- **Tailored assays drive 90%+ projected clinical trial success**
- **GigaAssay accelerates lead validation with vast libraries and MEGA-Map landscapes**

How? – With the GigaAssay


100k's of leads tested in human cells - *simultaneously*

>100k different IFN- α leads simultaneously

Cell-based GigaAssay measures bioactivity

Visualize GigaAssay data output for bioactivity

Purify, verify, patent leads for clinical testing





THANK YOU

Dr. Martin Schiller
mschiller@heligenics.com

Heligenics Inc.
10530 Discovery Drive
Las Vegas, NV 89135
www.heligenics.com

